Core Insights - The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Caribou Biosciences' CB-011 for relapsed or refractory multiple myeloma (r/r MM), recognizing the significant unmet medical need and promising clinical data from the ongoing CaMMouflage phase 1 trial [1][3] - CB-011 is an allogeneic anti-BCMA CAR-T cell therapy that has shown a 92% overall response rate (ORR) and a 75% complete response (CR) rate in a cohort of BCMA-naïve patients [2][4] - The ongoing dose expansion phase of the CaMMouflage trial is expected to provide additional data in 2026, with a focus on both BCMA-naïve and BCMA-exposed patient cohorts [1][5] Company Overview - Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for serious diseases, particularly hematologic malignancies [7] - The company is advancing CB-011 and vispacabtagene regedleucel (vispa-cel) as off-the-shelf CAR-T cell therapies aimed at improving patient access and treatment speed [7] Clinical Trial Details - The CaMMouflage phase 1 clinical trial is a multicenter, open-label study evaluating CB-011 in adults with r/r MM who have undergone three or more prior lines of therapy [5][6] - The trial has treated 48 patients in the dose escalation portion, with a recommended dose for expansion set at 450x10 CAR-T cells [2][6] - Safety data indicate a manageable profile for CB-011, with no cases of severe adverse events such as graft-versus-host disease reported [2][3]

Core Viewpoint - Caribou Biosciences, Inc. reported strong execution in 2025, advancing two allogeneic CAR-T cell therapy programs, vispa-cel and CB-011, with promising clinical data and ongoing engagement with the FDA for pivotal trial designs [2][8]. Financial Performance - Licensing and collaboration revenue for Q4 2025 was $3.9 million, and $11.2 million for the full year, an increase from $2.1 million and $10.0 million in 2024, driven by prior licensing agreements [6]. - R&D expenses decreased to $23.8 million in Q4 2025 and $109.4 million for the full year, down from $30.5 million and $130.2 million in 2024, primarily due to workforce reduction and strategic pipeline prioritization [7]. - General and administrative expenses were $8.6 million for Q4 2025 and $37.9 million for the full year, compared to $10.5 million and $46.5 million in 2024, reflecting lower legal and personnel-related expenses [9]. - Caribou reported a GAAP net loss of $26.5 million, or $0.28 per share, for Q4 2025, and a full-year net loss of $148.1 million, or $1.59 per share, compared to a net loss of $35.5 million, or $0.39 per share, and $149.1 million, or $1.65 per share, in 2024 [11]. - Non-GAAP net loss for 2025 was $126.8 million, or $1.36 per share, compared to $149.1 million, or $1.65 per share, in 2024, excluding non-cash impairment charges [12]. Clinical Highlights - Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, showed efficacy and durability comparable to autologous CAR-T therapies in the ANTLER phase 1 trial for second-line large B cell lymphoma (LBCL) [3][8]. - CB-011, an allogeneic anti-BCMA CAR-T cell therapy, is currently in the CaMMouflage phase 1 trial for relapsed or refractory multiple myeloma (r/r MM), with initial dose expansion data expected later in 2026 [4][8]. Upcoming Events - Caribou will participate in the Leerink 2026 Global Healthcare Conference on March 10, 2026, with a fireside chat scheduled for 8:00 am ET [5]. Cash Position - As of December 31, 2025, Caribou had $142.8 million in cash, cash equivalents, and marketable securities, down from $249.4 million in 2024, which is expected to fund operations into the second half of 2027 [13].

Core Insights - Caribou Biosciences, Inc. is hosting a panel discussion on vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, aimed at expanding patient access for second-line large B cell lymphoma treatment [1][2] Company Overview - Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for patients with severe diseases [6] - The company is advancing vispacabtagene regedleucel (vispa-cel), which is the first allogeneic CAR-T cell therapy in clinical trials with a PD-1 knockout designed to enhance CAR-T cell activity [4] Clinical Trial Information - The ANTLER phase 1 clinical trial is evaluating vispa-cel in adult patients with relapsed or refractory B cell non-Hodgkin lymphoma, with 84 patients treated as of September 2, 2025 [5] - The trial has shown positive data indicating that vispa-cel's efficacy and durability are comparable to autologous CAR-T cell therapies [5] Event Details - The expert panel discussion will take place in-person at the Hyatt Regency Orlando on December 6, 2025, and will also be available virtually [2][3] - The event will be moderated by Caribou's Chief Medical Officer, Dr. Tina Albertson, and will feature insights from leading physicians regarding access challenges and patient needs [2]

Core Insights - Caribou Biosciences Inc. reported significant advancements in its CAR-T therapy, showing complete and durable remissions in patients with advanced B-cell lymphoma [1][3] - The company’s stock surged by 17.56% following the announcement of positive trial results [6] Group 1: CAR-T Therapy Results - In the ongoing ANTLER phase 1 trial, 64% of patients achieved a complete response, while the overall response rate was 82% [3] - At one year, the progression-free survival rate was 51%, indicating that patients remained alive without cancer worsening [3] - The efficacy and durability of vispacel are comparable to autologous CAR-T cell therapies, based on data from a cohort of 35 patients [3] Group 2: Safety and Regulatory Insights - The therapy demonstrated a generally well-tolerated safety profile across all 84 patients treated in the ANTLER trial [4] - The FDA has recommended a randomized, controlled trial for second-line large B-cell lymphoma patients who are ineligible for transplant and autologous CAR-T therapy [4] - The company plans to conduct a pivotal phase 3 trial evaluating approximately 250 patients [4] Group 3: CB-011 Clinical Data - Caribou shared initial clinical data from the CaMMouflage Phase 1 trial of CB-011, an off-the-shelf anti-BCMA CAR-T cell therapy, showing a 92% overall response rate and a 75% complete response rate [5][6] - 91% of patients achieved minimal residual disease negativity, indicating no detectable cancer cells [6] - The company plans to advance the CB-011 program into dose expansion by the end of this year, with data expected in 2026 [5]

Core Insights - Caribou Biosciences, Inc. will present new data from the ANTLER phase 1 clinical trial for vispacabtagene regedleucel (vispa-cel) and the CaMMouflage Phase 1 trial for CB-011 on November 3, 2025 [1] - The company is focused on developing allogeneic CAR-T cell therapies for hematologic malignancies, specifically targeting relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma [1][5] Summary of vispacabtagene regedleucel (vispa-cel) - Vispacabtagene regedleucel is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma [3] - It is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, aimed at enhancing CAR-T cell activity by reducing premature exhaustion [3] - The therapy has received FDA designations including Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track for B-NHL [3] Summary of CB-011 - CB-011 is an allogeneic anti-BCMA CAR-T cell therapy being evaluated for relapsed or refractory multiple myeloma in the CaMMouflage Phase 1 trial [4] - It is the first allogeneic CAR-T cell therapy engineered with an immune cloaking strategy, featuring a B2M knockout and a B2M–HLA-E fusion protein to mitigate immune rejection [4] - CB-011 has also been granted Fast Track and Orphan Drug designations by the FDA [4] Company Overview - Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on transformative therapies for severe diseases [5] - The company's genome-editing platform utilizes Cas12a chRDNA technology for precise development of cell therapies [5] - Caribou aims to provide broad access and rapid treatment options through its off-the-shelf CAR-T cell therapies, vispacabtagene regedleucel and CB-011 [5]

Core Insights - Caribou Biosciences, Inc. will present new data from the ANTLER phase 1 clinical trial for vispacabtagene regedleucel (vispa-cel) and the CaMMouflage Phase 1 trial for CB-011 on November 3, 2025 [1] - The company is focused on developing allogeneic CAR-T cell therapies for hematologic malignancies, specifically targeting relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma [5] Group 1: Clinical Trials - The ANTLER trial evaluates vispacabtagene regedleucel (vispa-cel), an allogeneic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphoma [3] - The CaMMouflage trial assesses CB-011, an allogeneic anti-BCMA CAR-T cell therapy for patients with relapsed or refractory multiple myeloma [4] - Both therapies have received Fast Track and Orphan Drug designations from the FDA, indicating their potential significance in treating these conditions [3][4] Group 2: Technology and Innovation - Vispacabtagene regedleucel (vispa-cel) is noted for being the first allogeneic CAR-T cell therapy with a PD-1 knockout, aimed at enhancing CAR-T cell activity [3] - CB-011 is distinguished as the first allogeneic CAR-T cell therapy utilizing an immune cloaking strategy with a B2M knockout and B2M–HLA-E fusion protein [4] - Caribou's genome-editing platform employs Cas12a chRDNA technology, which allows for superior precision in developing cell therapies [5]

Core Insights - Caribou Biosciences, Inc. is a leading clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for patients with severe diseases [3] - The company will have its president and CEO, Rachel Haurwitz, participate in a fireside chat at the Citi 2025 Biopharma Back to School Conference on September 3, 2025 [1] Company Overview - Caribou's genome-editing platform utilizes Cas12a chRDNA technology, which allows for superior precision in developing cell therapies [3] - The company is concentrating on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies aimed at providing broad access and rapid treatment for patients with hematologic malignancies [3] Event Information - A webcast of the fireside chat will be available on Caribou's website for at least 30 days following the event [2]

Core Insights - Caribou Biosciences, Inc. is advancing its allogeneic CAR-T cell programs, CB-010 and CB-011, with robust clinical datasets expected to be disclosed in the second half of 2025 [1][2] - The company reported $184 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into the second half of 2027 [1][4] Clinical Programs - CB-010 is an allogeneic anti-CD19 CAR-T cell therapy targeting B cell non-Hodgkin lymphoma, while CB-011 is an anti-BCMA CAR-T cell therapy for multiple myeloma [3][11][12] - Both programs are generating encouraging Phase 1 results, reinforcing the potential of these therapies [2] Financial Performance - As of June 30, 2025, Caribou had $183.9 million in cash, down from $249.4 million at the end of 2024 [4][17] - Licensing and collaboration revenue for Q2 2025 was $2.7 million, a decrease from $3.5 million in Q2 2024 [5][18] - Research and development expenses were $27.7 million for Q2 2025, down from $35.5 million in the same period last year [5][18] Losses and Expenses - The company reported a net loss of $54.1 million, or $0.58 per share, for Q2 2025, compared to a net loss of $37.7 million, or $0.42 per share, for Q2 2024 [9][18] - Non-GAAP net loss for Q2 2025, excluding non-cash impairment charges, was $32.8 million, or $0.35 per share [9][19] Strategic Updates - Caribou is interacting with the FDA regarding a potential pivotal trial for CB-010, contingent on positive data and alignment [5][6] - The company plans to present data from both clinical trials in H2 2025, which will include initial safety and efficacy data [5][6]

Company Overview - Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for patients with severe diseases [3] - The company's genome-editing platform utilizes Cas12a chRDNA technology, which offers superior precision for developing cell therapies [3] - Caribou is concentrating on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies aimed at providing broad access and rapid treatment for patients with hematologic malignancies [3] Upcoming Events - Rachel Haurwitz, PhD, the president and CEO of Caribou, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4 at 9:20 AM EDT [1] - A link to the webcast of the event will be available on Caribou's website, and the webcasts will remain accessible for at least 30 days post-event [2]

Company Overview - Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for patients with severe diseases [3] - The company's genome-editing platform utilizes Cas12a chRDNA technology, which offers superior precision for developing cell therapies aimed at improving activity against diseases [3] Product Focus - Caribou is concentrating on two off-the-shelf CAR-T cell therapies, CB-010 and CB-011, which have the potential to provide broad access and rapid treatment for patients suffering from hematologic malignancies [3] Upcoming Events - Rachel Haurwitz, PhD, the president and CEO of Caribou, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT [1] - Webcasts of the event will be available on Caribou's website for at least 30 days following the event [2]